WINTON GROUP Ltd Has $7.56 Million Position in Solventum Corporation $SOLV

Posted by Francis Steltz on Jun 6th, 2026

WINTON GROUP Ltd raised its stake in shares of Solventum Corporation (NYSE:SOLV – Free Report) by 491.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 95,345 shares of the company’s stock after buying an additional 79,222 shares during the quarter. WINTON GROUP Ltd’s holdings in Solventum were worth $7,555,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after buying an additional 867,837 shares during the period. Independent Franchise Partners LLP grew its position in shares of Solventum by 27.2% during the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock worth $941,645,000 after buying an additional 2,758,174 shares during the period. State Street Corp grew its position in shares of Solventum by 1.8% during the 3rd quarter. State Street Corp now owns 6,220,271 shares of the company’s stock worth $454,080,000 after buying an additional 112,261 shares during the period. Davis Selected Advisers grew its position in shares of Solventum by 12.7% during the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after buying an additional 702,461 shares during the period. Finally, Boston Partners grew its position in shares of Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after buying an additional 959,543 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. BTIG Research reiterated a “buy” rating and issued a $89.00 price objective on shares of Solventum in a research report on Wednesday, May 6th. Piper Sandler dropped their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus dropped their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. KeyCorp raised their target price on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Wells Fargo & Company dropped their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Solventum presently has an average rating of “Moderate Buy” and an average price target of $84.25.

Read Our Latest Stock Analysis on Solventum

Solventum Stock Performance

Shares of SOLV stock opened at $81.07 on Friday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The company has a market capitalization of $14.04 billion, a P/E ratio of 9.93, a price-to-earnings-growth ratio of 1.27 and a beta of 0.69. The company’s 50 day moving average price is $70.91 and its two-hundred day moving average price is $75.21. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20.

Solventum (NYSE:SOLV – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the purchase, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. The trade was a 41.39% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.24% of the company’s stock.

About Solventum

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.